How much revenue does Sichuan Kelun-Biotech Biopharmaceutical make?

Sichuan Kelun-Biotech Biopharmaceutical reported 2.06 billion CNY in revenue for fiscal year 2025, up 6.5% from 1.93 billion CNY in fiscal year 2024.

Where does Sichuan Kelun-Biotech Biopharmaceutical make most of its revenue?

The United States of America: 64% of revenue by region in fiscal year 2025, followed by The PRC (28%).

What companies are similar to Sichuan Kelun-Biotech Biopharmaceutical?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Hansoh Pharmaceutical Group Company Limited (3692.HK), Innovent BIO (1801.HK), Akeso, Inc. (9926.HK), Shanghai Henlius Biotech, Inc. (2696.HK).

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) Stock

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People's Republic of China and internationally. The company's product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of ...

At a glance

Sichuan Kelun-Biotech Biopharmaceutical reported revenue of 2.06 billion CNY for fiscal year 2025, up 6.5% from fiscal year 2024, and net income of -381.97 million CNY. The United States of America was its largest region in fiscal year 2025, with 64% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.